Sheridan Capital Partners has completed an investment in Currier Plastics, a manufacturer of custom plastic components for medtech.
Currier Plastics CEO Andrew McClean
As part of the deal, Currier appointed Andrew McClean as CEO, effective immediately. He succeeds founder John Currier, who will remain with the company. McClean brings more than 25 years of leadership experience in the medical device and pharmaceutical industries. He previously served as CEO and president of SteriPack Group and as CEO of Sirtex. He has also held senior roles at BD and Pfizer.
“I am very proud of what our dedicated employees have created at Currier, and we have found a great partner in Sheridan to continue our steadfast commitment to excellence for our customers,” Currier said. “The healthcare expertise Sheridan brings will be invaluable as we look to execute on organic growth initiatives and strategic M&A. In addition, this partnership and the leadership of our incoming CEO Andrew McClean will enable us to continue to invest in the talent and operational resources to continue providing world-class products and services to our growing customer base across multiple end markets.”
Auburn, N.Y.-based Currier Plastics specializes in custom blow and injection molding with ISO Class 7 and Class 8 cleanroom production. Its offerings include design engineering, material selection and assembly.
“Currier is the result of our multi-year thesis in medical contract manufacturing and we are very excited to be partnering with them at this inflection point in their growth,” said Sean Dempsey, cofounder and partner at Sheridan.
Sheridan Principal Michael Bernard said the private equity firm plans to make additional resources available so Currier can expand its partnerships.
“Currier continues to win new business from highly demanding customers for a reason. We are excited to add even more resources to Currier so it can be the best possible partner to its customers,” Bernard said.
